Dyno Therapeutics
E661993
Dyno Therapeutics is a biotechnology company that uses artificial intelligence and machine learning to design optimized adeno-associated virus (AAV) gene therapy vectors.
All labels observed (1)
| Label | Occurrences |
|---|---|
| Dyno Therapeutics canonical | 1 |
How this entity was disambiguated
This entity first appeared as the object of triple T7392989 — resolving that mention is where its identity was fixed. The disambiguator weighed these candidate entities and picked the highlighted one (or “None”, minting a new entity). This is how homonymy is resolved: the same surface form can point to different entities.
NED1
Entity disambiguation (via context triple)
gpt-5-mini-2025-08-07
Target entity: Dyno Therapeutics Context triple: [George Church, coFounded, Dyno Therapeutics]
-
A.
Insitro
Insitro is a biotechnology company that uses machine learning and high-throughput biology to accelerate drug discovery and development.
-
B.
Nautilus Biotechnology
Nautilus Biotechnology is a life sciences company developing next-generation, high-throughput proteomics platforms to enable comprehensive analysis of the human proteome for research and drug discovery.
-
C.
Ridgeback Biotherapeutics
Ridgeback Biotherapeutics is a biotechnology company focused on developing antiviral and immunotherapy treatments for serious infectious diseases, including Ebola and COVID-19.
-
D.
Juno Therapeutics
Juno Therapeutics is a biotechnology company focused on developing cutting-edge immunotherapies, particularly CAR-T cell treatments, for cancer.
-
E.
Array BioPharma
Array BioPharma is a biopharmaceutical company known for developing targeted small-molecule cancer therapies, particularly in oncology and rare diseases.
- F. None of above. chosen
- G. Unsure - the case is ambiguous/there is not enough information to decide.
NED2
Entity disambiguation (via description)
gpt-5-mini-2025-08-07
Target entity: Dyno Therapeutics Target entity description: Dyno Therapeutics is a biotechnology company that uses artificial intelligence and machine learning to design optimized adeno-associated virus (AAV) gene therapy vectors.
-
A.
Insitro
Insitro is a biotechnology company that uses machine learning and high-throughput biology to accelerate drug discovery and development.
-
B.
Nautilus Biotechnology
Nautilus Biotechnology is a life sciences company developing next-generation, high-throughput proteomics platforms to enable comprehensive analysis of the human proteome for research and drug discovery.
-
C.
Ridgeback Biotherapeutics
Ridgeback Biotherapeutics is a biotechnology company focused on developing antiviral and immunotherapy treatments for serious infectious diseases, including Ebola and COVID-19.
-
D.
Juno Therapeutics
Juno Therapeutics is a biotechnology company focused on developing cutting-edge immunotherapies, particularly CAR-T cell treatments, for cancer.
-
E.
Array BioPharma
Array BioPharma is a biopharmaceutical company known for developing targeted small-molecule cancer therapies, particularly in oncology and rare diseases.
- F. None of above. chosen
Statements (43)
| Predicate | Object |
|---|---|
| instanceOf | biotechnology company ⓘ |
| aimsTo |
enable next-generation gene therapies
ⓘ
improve efficacy of gene therapies ⓘ improve safety of gene therapies ⓘ improve tissue targeting of AAV vectors ⓘ |
| basedIn | Cambridge, Massachusetts NERFINISHED ⓘ |
| businessModel | platform company ⓘ |
| country |
United States of America
ⓘ
surface form:
United States
|
| develops |
AAV capsid libraries
ⓘ
gene delivery vectors ⓘ |
| field |
computational biology
ⓘ
gene delivery engineering ⓘ synthetic biology ⓘ |
| focusesOn |
AAV gene therapy vectors
ⓘ
adeno-associated virus vectors ⓘ gene therapy ⓘ |
| foundedIn | 2018 ⓘ |
| hasCollaborationWith |
Astellas
NERFINISHED
ⓘ
Lilly NERFINISHED ⓘ Novartis NERFINISHED ⓘ Roche NERFINISHED ⓘ Spark Therapeutics NERFINISHED ⓘ |
| hasFounder |
Eric Kelsic
NERFINISHED
ⓘ
George Church NERFINISHED ⓘ Sam Sinai NERFINISHED ⓘ |
| hasKeyPerson |
Eric Kelsic
NERFINISHED
ⓘ
George Church NERFINISHED ⓘ Sam Sinai NERFINISHED ⓘ |
| hasTechnology | AI-powered capsid design platform ⓘ |
| industry | biotechnology ⓘ |
| offers | AAV capsid discovery partnerships ⓘ |
| originatedFrom |
Harvard University
NERFINISHED
ⓘ
Wyss Institute for Biologically Inspired Engineering NERFINISHED ⓘ |
| specializesIn |
capsid engineering
ⓘ
design of optimized AAV vectors ⓘ |
| targets |
central nervous system gene therapy
ⓘ
in vivo gene therapy applications ⓘ ocular gene therapy ⓘ systemic gene delivery ⓘ |
| usesMethod |
artificial intelligence
ⓘ
data-driven optimization of AAV capsids ⓘ high-throughput in vivo screening ⓘ machine learning ⓘ |
How these facts were elicited
The pipeline generated the facts above by prompting gpt-5.1 with this entity's name + description and the instruction below.
Instruction
You are a knowledge base construction expert. Given a subject entity and a description of it, return factual statements that you know for the subject as a JSON list of dictionaries(triples), where keys must be "subject", "predicate" and "object". The number of facts may be very high, between 25 to 50 or more, for very popular subjects. For less popular subjects, the number of facts can be very low, like 5 or 10. # Requirements - If you don't know the subject at all, return an empty list. - If the subject is not a named entity, return an empty list. - Include at least one triple where predicate is "instanceOf". - Do not get too wordy. - Separate several objects into multiple triples with one object.
Input
Subject: Dyno Therapeutics Description of subject: Dyno Therapeutics is a biotechnology company that uses artificial intelligence and machine learning to design optimized adeno-associated virus (AAV) gene therapy vectors.
Referenced by (1)
Full triples — surface form annotated when it differs from this entity's canonical label.